Myriad Corporate Presentation
Myriad Annual Report 2018

News Releases | Subscribe

August 13, 2019

Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2019 Financial Results

Total Fourth-Quarter Revenues of $215.4 Million Fourth-Quarter Diluted EPS of ($0.06) and Adjusted EPS of $0.41 SALT LAKE CITY, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today

Read More

August 7, 2019

Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer

SALT LAKE CITY, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, today announced that the AstraZeneca/Merck Phase III PROfound study (NCT02987543) demonstrated that men with metastatic castration-resistant

Read More

August 6, 2019

Myriad to Announce Fiscal Fourth-Quarter 2019 Financial Results on August 13, 2019

SALT LAKE CITY, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will hold its fiscal fourth-quarter 2019 sales and earnings conference call with investors and analysts at 4:30 p.m.

Read More

August 13, 2019

Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2019 Financial Results

Total Fourth-Quarter Revenues of $215.4 Million Fourth-Quarter Diluted EPS of ($0.06) and Adjusted EPS of $0.41 SALT LAKE CITY, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today

Read More

August 6, 2019

Myriad to Announce Fiscal Fourth-Quarter 2019 Financial Results on August 13, 2019

SALT LAKE CITY, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will hold its fiscal fourth-quarter 2019 sales and earnings conference call with investors and analysts at 4:30 p.m.

Read More

May 7, 2019

Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results

Total Third-Quarter Revenues of $216.6 Million, Up 18 Percent Third-Quarter Diluted EPS of $0.09 and Adjusted EPS of $0.46, Up 35 Percent SALT LAKE CITY, May 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in personalized medicine, today

Read More

August 6, 2019

Myriad to Announce Fiscal Fourth-Quarter 2019 Financial Results on August 13, 2019

SALT LAKE CITY, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will hold its fiscal fourth-quarter 2019 sales and earnings conference call with investors and analysts at 4:30 p.m.

Read More

June 5, 2019

Myriad Genetics to Present at the 2019 Goldman Sachs Global Healthcare Conference

SALT LAKE CITY, June 05, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the Goldman Sachs Global Healthcare Conference at 11:40 a.m.

Read More

May 1, 2019

Myriad Genetics to Present at Two Upcoming Healthcare Conferences

SALT LAKE CITY, May 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that it will be presenting at two upcoming healthcare conferences. R. Bryan Riggsbee, chief financial officer, will present at the Bank of

Read More

August 7, 2019

Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer

SALT LAKE CITY, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, today announced that the AstraZeneca/Merck Phase III PROfound study (NCT02987543) demonstrated that men with metastatic castration-resistant

Read More

June 27, 2019

Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer

Validation Study Shows Prolaris Test Identifies Men Who May Benefit from Surgery or Radiation at the Time of a Prostate Cancer Diagnosis SALT LAKE CITY, June 27, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced publication of

Read More

June 25, 2019

Myriad Announces Publication of First Comprehensive Economic Study Demonstrating Cost Effectiveness of EndoPredict® for Breast Cancer

Findings Show EndoPredict Was Significantly More Cost Effective than Oncotype DX™ SALT LAKE CITY, June 25, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that The Pharmacogenomics Journal published the results of the first

Read More

August 7, 2019

Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer

SALT LAKE CITY, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, today announced that the AstraZeneca/Merck Phase III PROfound study (NCT02987543) demonstrated that men with metastatic castration-resistant

Read More

June 27, 2019

Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer

Validation Study Shows Prolaris Test Identifies Men Who May Benefit from Surgery or Radiation at the Time of a Prostate Cancer Diagnosis SALT LAKE CITY, June 27, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced publication of

Read More

June 3, 2019

Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology

SALT LAKE CITY, June 03, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that results from two studies of the myRisk ® Hereditary Cancer test will be featured today in presentations at the annual meeting of

Read More